Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

被引：0

作者：

Bally, Cecile ^{[1
]}

Ades, Lionel ^{[2
]}

Renneville, Aline ^{[3
]}

Preudhomme, Claude ^{[4
]}

Mozziconacci, Marie-Joelle ^{[5
]}

de The, Hugues ^{[6
]}

Lehmann-Che, Jacqueline ^{[6
]}

Fenaux, Pierre ^{[2
]}

机构：

[1] Hop Avicenne, Hematol Clin, F-93009 Bobigny, France

[2] Univ Paris 13, Hop Avicenne, AP HP, Dept Hematol, Paris, France

[3] CHRU Lille, Ctr Biol Pathol, Lab Hematol, Lille, France

[4] Univ Lille, CHRU Lille, Lille, France

[5] Inst J Paoli I Calmettes, Lab Mol Biol & Cytogenet, F-13009 Marseille, France

[6] Univ Paris, Hosp St Louis, F-75252 Paris, France

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.1706.1706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1706

引用

页数：2

共 50 条

[1] Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)
Bally, C.
Ades, L.
Renneville, A.
Mozziconacci, M. J.
Preudhomme, C.
DeThe, H.
Lehmann-Che, J.
Fenaux, P.
LEUKEMIA RESEARCH, 2013, 37 : S25 - S25
[2] Response to azacitidine is independent of TP53 mutations in higher-risk MDS
Mueller-Thomas, C.
Rudelius, M.
Wolf, P.
Schmidt, B.
Platzbecker, U.
Germing, U.
Peschel, C.
Gotze, K.
ONKOLOGIE, 2012, 35 : 31 - 31
[3] Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine
Bally, Cecile
Ades, Lionel
Renneville, Aline
Sebert, Marie
Eclache, Virginie
Preudhomme, Claude
Mozziconacci, Marie-Joelle
de The, Hugues
Lehmann-Che, Jacqueline
Fenaux, Pierre
LEUKEMIA RESEARCH, 2014, 38 (07) : 751 - 755
[4] Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine
Zeidan, Amer M.
Bewersdorf, Jan Philipp
Hasle, Vanessa
Shallis, Rory M.
Thompson, Ethan
de Menezes, Daniel Lopes
Rose, Shelonidta
Boss, Isaac
Halene, Stephanie
Haferlach, Torsten
Fox, Brian A.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[5] Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.
Bally, Cecile
Ades, Lionel
Renneville, Aline
Raynaud, Sophie
Eclache, Virginie
Cluzeau, Thomas
Hunault-Berger, Mathilde
Stamatoullas, Aspasia
Bastard, Christian
Fontenay, Michaela
Mozziconacci, Marie-Joelle
Preudhomme, Claude
de The, Hugues
Fenaux, Pierre
Lehmann-Che, Jacqueline
BLOOD, 2012, 120 (21)
[6] PROGNOSTIC VALUE OF TP53 MUTATIONS IN CHILDHOOD MEDULLOBLASTOMA
Pfaff, E.
Remke, M.
Sturm, D.
Witt, H.
von Bueren, A.
Wittmann, A.
Schoettler, A.
Scheurlen, W.
Kulozik, A. E.
Witt, O.
von Deimling, A.
Rutkowski, S.
Hawkins, C.
Tabori, U.
Lichter, P.
Korshunov, A.
Pfister, S. M.
NEURO-ONCOLOGY, 2010, 12 (06) : II3 - II3
[7] TP53 mutations and Azacitidine treatment: To be or not to be related?
Rigolin, Gian Matteo
Cuneo, Antonio
LEUKEMIA RESEARCH, 2014, 38 (07) : 727 - 728
[8] Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Mueller-Thomas, Catharina
Rudelius, Martina
Rondak, Ina
Haferlach, Torsten
Schanz, Julie
Schmidt, Burkhard
Kremer, Markus
Germing, Ulrich
Platzbecker, Uwe
Peschel, Christian
Goetze, Katharina
BLOOD, 2013, 122 (21)
[9] The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients
Belickova, Monika
Vesela, Jitka
Jonasova, Anna
Stara, Eliska
Planetova, Barbora
Zemanova, Zuzana
Brezinova, Jana
Mikulenkova, Dana
Cermak, Jaroslav
BLOOD, 2014, 124 (21)
[10] Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
Bories, Pierre
Prade, Nais
Lagarde, Stephanie
Cabarrou, Bastien
Largeaud, Laetitia
Plenecassagnes, Julien
Luquet, Isabelle
De Mas, Veronique
Filleron, Thomas
Cassou, Manon
Sarry, Audrey
Fornecker, Luc-Matthieu
Simand, Celestine
Bertoli, Sarah
Recher, Christian
Delabesse, Eric
PLOS ONE, 2020, 15 (10):

← 1 2 3 4 5 →